Key statistics
On Monday, BeOne Medicines AG (6160:HKG.HS) closed at 205.80, -10.29% below its 52-week high of 229.40, set on Nov 13, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 212.00 |
|---|---|
| High | 214.00 |
| Low | 203.20 |
| Bid | 205.60 |
| Offer | 205.80 |
| Previous close | 208.60 |
| Average volume | 2.83m |
|---|---|
| Shares outstanding | 1.54bn |
| Free float | 1.33bn |
| P/E (TTM) | 657.68 |
| Market cap | 329.79bn HKD |
| EPS (TTM) | 0.3129 HKD |
Data delayed at least 15 minutes, as of Feb 16 2026 04:08 GMT.
More ▼
Press releases
- BeOne Medicines to Present at Upcoming Investor Conferences
- BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
- BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
- ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
- BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
- BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
- BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
- Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
- U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
More ▼
